new version V2017

SGLT2 inhibitors
Description Results

Dapagliflozin - Empagliflozin - Ertugliflozin      

  • Group by...

TrialStudied treatmentControl treatmentpatientsROBResultNCT

diabetes type 2

canagliflozin
3005: monotherapy ongoing canagliflozinplacebo -
CANTATA-D ongoing canagliflozinplacebo (add-on MET) - NCT01106677
3008: Add-on to insulin ongoing canagliflozinplacebo (add-on MET) -
3009: Add-on to MET ongoing canagliflozinplacebo (add-on MET) -
3002: Add-on to MET + SU ongoing canagliflozinplacebo (add-on MET+SU) -
3015: Add-on to MET + SU ongoing canagliflozinplacebo (add-on MET+SU) -
3012: Add-on to MET +TZD ongoing canagliflozinplacebo (add-on MET+TZD) -
3008: Add-on to SU ongoing canagliflozinplacebo (add-on SU) -
dapagliflozin
Kohandapagliflozinplacebo - NCT00972244
Weberdapagliflozinplacebo (on top standard treatment) - NCT01195662
MB102035dapagliflozinplacebo (on top standard treatment) - NCT00976495
MB102073dapagliflozinplacebo (on top standard treatment) - NCT01137474
MB102061dapagliflozinplacebo add on DPP-4 - NCT00984867
Kohandapagliflozin + merformindapagliflozin - NCT00643851
Kohandapagliflozinplacebo - NCT00663260
KOhandapagliflozinplacebo Low risk of bias - NCT00736879
Komoroski (MB102007), 2009dapagliflozinplacebo Exploratory - NCT00162305
List (MB102008), 2009dapagliflozinplacebo Exploratory - NCT00263276
Wilding (MB102009), 2009dapagliflozinplacebo (add on insulin) - NCT00357370
Ferrannini (MB102013), 2010dapagliflozinplacebo - NCT00528372
Bailey (MB102014), 2010dapagliflozinplacebo (add on MET) Exploratory - NCT00528879
Nauck, 2011dapagliflozindlipizide add on metformin - NCT00660907
Strojek, 2011dapagliflozin + Glimepirideglimepiride - NCT00680745
Wilding, 2012dapagliflozinplacebo (add on insulin) - NCT00673231
Bolinder, 2012dapagliflozinplacebo (add on MET) - NCT00855166
Rosenstock, 2012dapagliflozinplacebo (add on TZD) - NCT00683878
Kaku, 2014dapagliflozinplacebo - NCT01294423
Yang, 2015dapagliflozin - NCT01095666
Mathieu, 2015dapagliflozinplacebo (add on MET + SAXA) - NCT01646320
Schumm-Draeger , 2015dapagliflozinplacebo (add on MET) - NCT01217892
Matthaei, 2015dapagliflozinplacebo (add on MET+SU) - NCT01392677
Cefalu, 2015dapagliflozinplacebo (on top standard treatment) - NCT01031680
Rosenstock, 2015dapagliflozinSaxagliptin (add on MET) - NCT01606007
MB102034, 2016dapagliflozin + merforminmetformin or dapa - NCT00859898
Leiter, 2016dapagliflozinplacebo (on top standard treatment) - NCT01042977
D1695C00001 ongoing dapagliflozindapagliflozin - NCT02582814
MB102-210 ongoing dapagliflozinplacebo - NCT02383238
DERIVE ongoing dapagliflozinplacebo - NCT02413398
DECLARE-TIMI 58 ongoing dapagliflozinplacebo - NCT01730534
D1693C00002 ongoing dapagliflozinplacebo - NCT01257412
D1690C00023 ongoing dapagliflozinplacebo - NCT02547935
D5553C00003 ongoing dapagliflozinplacebo (add on EXE) - NCT02229396
MB102-137 ongoing dapagliflozinplacebo (add on INS) - NCT02096705
D1683C00005 ongoing dapagliflozinplacebo (add on SAXA + MET) - NCT02681094
MB102-054 ongoing dapagliflozinplacebo (add-on MET) - NCT01095653
CV181-363 ongoing dapagliflozinsaxa (add on MET) - NCT02284893
CV181-365 ongoing dapagliflozinSaxagliptin (add on MET) - NCT02419612
0431-838 ongoing dapagliflozinSitagliptin (add on mET) - NCT02532855
empagliflozin
EMPA-REG OUTCOMEempagliflozinplacebo - NCT01131676
Kadowaki, 2013empagliflozin -
Ferrannini, 2013empagliflozinplacebo - NCT00789035
EMPA-REG MONO (Roden) vs placebo, 2013empagliflozinplacebo - NCT01177813
EMPA-REG PIO (Kovacs), 2013empagliflozinplacebo (add on MET+/-PIO) - NCT01210001
Rosenstock DOUBLON ???, 2013empagliflozinplacebo (add-on INS) -
Rosenstock, 2013empagliflozinplacebo (add-on MET) - NCT00749190
Kadowaki , 2014empagliflozin -
Ridderstrale, 2014empagliflozinGlimepiride + MET - NCT01167881
Barnett, 2014empagliflozinplacebo - NCT01164501
Rosenstock (1245.49), 2014empagliflozinplacebo (add-on INS+/-MET) - NCT01306214
EMPA-REG MET (Haring), 2014empagliflozinplacebo (add-on MET) - NCT01159600
DeFronzo, 2015empagliflozinlinagliptin (add-on MET) - NCT01422876
Lewin, 2015empagliflozinlinagliptin (monotherapy) - NCT01422876
Kadowaki, 2015empagliflozinplacebo - NCT01193218
Ross, 2015empagliflozinplacebo (add-on MET) - e2012-000905-53
Araki, 2015empagliflozinplacebo (add-on standard treatment) - NCT01368081
1275.9 ongoing empagliflozinadd-on linagliptin + MET - NCT01734785
1276.1 (bitherapy MET) ongoing empagliflozin + METMET - NCT01719003
1245.29 ongoing empagliflozinplacebo - NCT02182830
99050 ongoing empagliflozinplacebo (add on MET+/-SU) - NCT01257334
EASE-2 ongoing empagliflozinPlacebo (add-on INS) - NCT02414958
1275.19 ongoing empagliflozinplacebo add-on linagliptin - NCT02453555
saxagliptin
CV181-369 ongoing Saxagliptin/DapagliflozinGlargine insulin - NCT02551874



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons